VIDEO: ADAURA holds spotlight with continued ‘maturity,’ lung cancer success
Click Here to Manage Email Alerts
In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, discussed findings from the ADAURA trial presented at ESMO Virtual Congress 2020.
Herbst, who also serves as ensign professor of medicine and professor of pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, first presented data from the ADUARA trial at ASCO earlier this summer while his colleague, Masahiro Tsuboi, discussed the findings in a plenary session at ESMO.
“The second time around, it’s just as good,” Herbst said of the trial that looked at treatment of lung cancer with osimertinib (Tagrisso, AstraZeneca).
He explained further that the hazard ratio for disease-free survival among patients with stage 2 or 3 disease who received osimertinib after surgery stayed consistent from the ASCO presentation to ESMO’s presentation. However, the hazard ratio, which included patients with stage 1, 2 and 3 disease, demonstrated an 80% improvement.
“With a little bit more maturity, the data continue to look quite good,” Herbst said.
The data presented at ESMO also highlighted the activity of osimertinib in the brain and its impact on disease recurrence.
References:
- Tsuboi M, et al. Abstract LBA1. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts